Canntab Therapeutics Limited Stock Retained Earnings
CTABF Stock | USD 0.0001 0.00 0.00% |
Canntab Therapeutics Limited fundamentals help investors to digest information that contributes to Canntab Therapeutics' financial success or failures. It also enables traders to predict the movement of Canntab Pink Sheet. The fundamental analysis module provides a way to measure Canntab Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Canntab Therapeutics pink sheet.
Canntab |
Canntab Therapeutics Limited Company Retained Earnings Analysis
Canntab Therapeutics' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
Competition |
Based on the latest financial disclosure, Canntab Therapeutics Limited has a Retained Earnings of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The retained earnings for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Money Managers Now
Money ManagersScreen money managers from public funds and ETFs managed around the world |
All Next | Launch Module |
Canntab Fundamentals
Return On Equity | -6.02 | |||
Return On Asset | -0.82 | |||
Operating Margin | (26.95) % | |||
Current Valuation | 1.73 M | |||
Shares Outstanding | 38.91 M | |||
Shares Owned By Insiders | 15.08 % | |||
Price To Book | 4.74 X | |||
Price To Sales | 1.83 X | |||
Revenue | 293.36 K | |||
Gross Profit | (939.01 K) | |||
EBITDA | (2.49 M) | |||
Net Income | (3.69 M) | |||
Cash And Equivalents | 691.11 K | |||
Cash Per Share | 0.02 X | |||
Total Debt | 126.2 K | |||
Debt To Equity | 2.43 % | |||
Current Ratio | 0.57 X | |||
Book Value Per Share | (0.04) X | |||
Cash Flow From Operations | (2.85 M) | |||
Earnings Per Share | (0.1) X | |||
Beta | 0.9 | |||
Market Capitalization | 774.29 K | |||
Total Asset | 2.85 M | |||
Z Score | 3.6 | |||
Net Asset | 2.85 M |
About Canntab Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Canntab Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Canntab Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Canntab Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Canntab Pink Sheet
Canntab Therapeutics financial ratios help investors to determine whether Canntab Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Canntab with respect to the benefits of owning Canntab Therapeutics security.